To broaden the operating temperature range of phosphoric acid (PA) doped polybenzimidazole membrane-based proton exchange membrane fuel cells (PEMFCs) toward low temperatures, a novel series of poly(2,5-benzimidazole) (ABPBI)/sulfonated sepiolite (S-Sep) composite membranes (ABPBI/S-Sep) with low PA doping levels (DLs) were prepared via in-situ synthesis. The desirably enhanced mechanical, thermal, and oxidative stabilities of ABPBI/S-Sep composite membranes were achieved by constructing ABPBI chains arranged along the sepiolite (Sep) fibers 2 and acid-base crosslinks formed between S-Sep fibrous particles and ABPBI chains. Benefiting from the richness of high temperature stable bound water and the excellent water absorbability of Sep particles that enable the formation of additive proton conducting paths, the composite membranes retained bounded PA and achieved much higher proton conductivities under both anhydrous and hydrous conditions compared to PA-doped ABPBI membranes. Proton conductivity values above 0.01 S/cm at 40-90 °C/20-98% RH conditions and 90-180 °C/anhydrous conditions as well as peak power density of 0.13 and 0.23 W/cm 2 at 80 and 180 °C with 0% RH, respectively from the ABPBI/2S-Sep composite membrane are more holistic compared to Nafion at low temperatures and polybenzimidazole-based membranes at high temperatures, respectively. The excellent properties of ABPBI/S-Sep composite membranes suggest them as prospective candidates for PEMFCs applications in a wide temperature range.
Targeted therapies are efficient in the context of oncogenic driver mutations. Epidermal growth factor receptor (EGFR)-mutant lung cancers represent a distinct subset of non-small-cell lung cancer (NSCLC) with marked sensitivity to EGFR tyrosine kinase inhibitors (TKIs). Despite the high response rate to EGFR TKIs in EGFR-mutant lung cancer, resistance and tumor recurrence are unavoidable. Therapeutic options are restricted in patients after exhaustion of targeted therapies. Immune checkpoint inhibitors (ICIs) represent a novel therapeutic option for advanced NSCLC with significant overall survival benefit in registration trials. No superiority in terms of long-term survival was observed in the EGFR mutation subgroup when ICIs were given as monotherapy in second-line treatment in earlier studies. Thus, the appropriate application of ICIs to patients harboring EGFR mutations remains an important field of ongoing research. Here, we discuss different immune checkpoint blockade strategies, including ICIs alone and in combination with TKIs, chemotherapy, radiation, and antiangiogenic agents in EGFR-mutant NSCLC as first-line and subsequent treatments. We also summarize the evidence concerning the heterogeneous molecular features and immune signatures of EGFR mutations and their associations with ICI therapy outcomes. This study was performed to improve our understanding of the optimal mode of immune-based treatment approaches in EGFR-mutant NSCLC.
This study introduces an easy method of preparing xyloglucan hydrogel from xyloglucan, which is purified from tamarind seed gum. Xyloglucan hydrogel was prepared in 2 wt% solution by treating with β-galactosidase. Physical and chemical properties (molecular mass, size and viscosity) of xyloglucan hydrogel and xyloglucan solution were tested for a comparison. Experiments of drug release in vitro and in vivo were operated to investigate the potentialities of xyloglucan hydrogel as the biomedical sustained-release carriers for drug delivery system.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.